WO1999023056A1 - Nouveaux medicaments anti-convulsions - Google Patents
Nouveaux medicaments anti-convulsions Download PDFInfo
- Publication number
- WO1999023056A1 WO1999023056A1 PCT/RU1997/000350 RU9700350W WO9923056A1 WO 1999023056 A1 WO1999023056 A1 WO 1999023056A1 RU 9700350 W RU9700350 W RU 9700350W WO 9923056 A1 WO9923056 A1 WO 9923056A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salts
- compounds
- relates
- well
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/12—Saturated polycyclic compounds
- C07C61/125—Saturated polycyclic compounds having a carboxyl group bound to a condensed ring system
- C07C61/13—Saturated polycyclic compounds having a carboxyl group bound to a condensed ring system having two rings
Definitions
- the invention is available for the manufacture of new medicinal devices that are equipped with a proprietary vessel.
- Advantageous activities may have a bearing on various substances that weaken the excitation process or enhance the process of mediation in the central non-payload system.
- One of the best known ship ships of 25 is a phenobital.
- diphenin, hexamidine, diazepam, clones, etoxusimide and others are also used.
- the present invention is subject to 0 new derivatives of bicycles [2, 2, 2] of oxo-2-carboxylic acid I.
- the resulting salts are 5 non-toxic compounds that are well-disposed in water and reasonably moderate in ethanol, are stable in emergency and in disinfectant. They are not hygienic, do not have stable crystalline hydrates, and aqueous products have a neutral reaction.
- the structure and composition of the obtained 0 salts are confirmed by the data of elemental analysis, as well as by the methods of research and experimentation.
- the invention also includes methods of practical use of the declared compounds by introducing the principle of compounds of the formula I in the 5th used for the consolidated use. Ways to get rid of the therapeutic, pharmacological and pharmaceutical use.
- 10 is used in its general sense, which includes exclusion, restraint, mitigation of the severity of the disease or symptom, or its consequence.
- compositions of a predominantly 5 exist in the form of accrued units calculated for the receipt of the desired therapeutic effect. They can be administered orally in the form of tablets, capsules, or powders, in the form of generic, internal or external injections, and are used internally.
- the declared salts are converted to the corresponding products with 0 use of pharmaceuticals or diluents.
- the inventive invention is illustrated by the communication methods and data on the pharmaceutical activity of the claimed compounds.
- a solution of 0.18 mol ⁇ or ⁇ or 0.9 mol 25 in water contains 0.2 ml of bicyclic acid [2, 2, 2] acid 2 with ⁇ . ⁇ l. 84-86 ° C, 1 hour ⁇ e ⁇ emeshivayu ⁇ ⁇ i ⁇ mna ⁇ n ⁇ y ⁇ em ⁇ e ⁇ a ⁇ u ⁇ e, izby ⁇ ⁇ isl ⁇ y ⁇ il ⁇ vyvayu ⁇ or izvle ⁇ ayu ⁇ ⁇ ganiches ⁇ im ⁇ as ⁇ v ⁇ i ⁇ elem, v ⁇ dny ⁇ as ⁇ v ⁇ 30 u ⁇ a ⁇ ivayu ⁇ in va ⁇ uume d ⁇ su ⁇ a ⁇ i 120-140 ° C ⁇ luchayu ⁇ na ⁇ ievuyu s ⁇ l, vy ⁇ d 93 ⁇ . ⁇ l.
- STRUCTURAL-CHARACTERISTIC are 0 areas of valency vibrations of large anion-doubles at 1570-1554 and 1420-1411 cm ⁇ 1 in oil; a multiplet of 2.42 ppm, corresponding to ⁇ -negative, in the case of a direct magnetic resonance (200.13 MHz, ⁇ ⁇ ⁇ ); Nine 5 signals at 21.72, 23.71 ( ⁇ 4 ), 24.75, 24.96, 26.03, 27.71 ( ⁇ ), 29.03, 44.22 and 185.65 ( ⁇ -) ppm in a carbon-magnetic resonance spectrum (50.31 MHz, ⁇ ⁇ ⁇ ). Obtained by this method, the sodium salt is not active in the optical activity. 0
- magnesium salt is bicyclic [2, 2, 2]
- 35 is apt to be optically inactive.
- the hazardous substance (propylene oxide) - the testing agent - is one of the most dispersed shipping agents that cause personal injury.
- the studied drug was alive in 15-25 minutes. before testing in a dose of 200 mg / kg, and
- the latent process was detected before the occurrence of motor excitation and all subsequent stages, the strength and duration of the motor reactions and the actual shipping phase.
- the claimed compounds are distinguished by the design of all of the known medical devices received by us.
- phenoben 20 frames of the same method with well-known standards from different classes of courthouse products: phenoben, diphenin and konvuleksom (table 4). Reacted in doses of 15-30 mg / kg, weakening the severity of seizure, causes depression of a total of 25 motor activity, attack, dormancy, i.e. genealogy transmission. Diphenin at a dose of 20 mg / kg slightly weakens the severity of the seizure without pronounced “ acute” effect and slightly lengthens the latent foods, not
- 35 may be attributed to low-dose drugs of the 4th group. .
- the first dose was 29 mg / kg
- the second dose was 200 mg / kg
- the dose was 600 mg / kg each dose.
- Sacracin did not have a noticeable effect on livelihoods and on conditionally-reflexive activity, i.e. on memory processes (fig. 1).
- 20 sensitivities of a cholinergic patient is a neuropsychiatric one.
- the dose of the drug before the start of the drug is founded on founded on a dose of the drug before the start of the drug.
- Sensitization - Solution Medium Medium, mg / kg mg / kg live (+) -analysis.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU64254/98A AU6425498A (en) | 1997-11-05 | 1997-11-05 | New anticonvulsant drugs |
PCT/RU1997/000350 WO1999023056A1 (fr) | 1997-11-05 | 1997-11-05 | Nouveaux medicaments anti-convulsions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU1997/000350 WO1999023056A1 (fr) | 1997-11-05 | 1997-11-05 | Nouveaux medicaments anti-convulsions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999023056A1 true WO1999023056A1 (fr) | 1999-05-14 |
Family
ID=20130159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1997/000350 WO1999023056A1 (fr) | 1997-11-05 | 1997-11-05 | Nouveaux medicaments anti-convulsions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU6425498A (fr) |
WO (1) | WO1999023056A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071872A2 (fr) | 2008-12-20 | 2010-06-24 | Ase Pharmaceuticals, Llc | Dérivés bicycliques (2.2.2) et leurs procédés d'utilisation |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2065104A (en) * | 1979-10-26 | 1981-06-24 | Secr Defence | Liquid Crystal Bicyclo-octane Compounds |
FR2547814A1 (fr) * | 1983-06-22 | 1984-12-28 | Sanofi Sa | Derives de l'acide bicyclo (3.2.1.) octane carboxylique, leur procede de preparation et leur application therapeutique |
EP0132964A2 (fr) * | 1983-06-29 | 1985-02-13 | Richter Gedeon Vegyeszeti Gyar R.T. | Dérivés de 2-azabicyclo[2,2,2]-octane |
US4826866A (en) * | 1987-11-02 | 1989-05-02 | A. H. Robins Company, Incorporated | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics |
US4956124A (en) * | 1987-05-11 | 1990-09-11 | Henkel Kommanditgesellschaft Auf Aktien | Bicyclic decanedioic acids, a process for their production, and their use as flotation aids |
RU2091366C1 (ru) * | 1992-06-16 | 1997-09-27 | Инесса Ивановна Крицкая | Натриевая соль бицикло(2.2.2.)октан -2-карбоновой кислоты, проявляющая противосудорожную активность |
-
1997
- 1997-11-05 AU AU64254/98A patent/AU6425498A/en not_active Abandoned
- 1997-11-05 WO PCT/RU1997/000350 patent/WO1999023056A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2065104A (en) * | 1979-10-26 | 1981-06-24 | Secr Defence | Liquid Crystal Bicyclo-octane Compounds |
FR2547814A1 (fr) * | 1983-06-22 | 1984-12-28 | Sanofi Sa | Derives de l'acide bicyclo (3.2.1.) octane carboxylique, leur procede de preparation et leur application therapeutique |
EP0132964A2 (fr) * | 1983-06-29 | 1985-02-13 | Richter Gedeon Vegyeszeti Gyar R.T. | Dérivés de 2-azabicyclo[2,2,2]-octane |
US4956124A (en) * | 1987-05-11 | 1990-09-11 | Henkel Kommanditgesellschaft Auf Aktien | Bicyclic decanedioic acids, a process for their production, and their use as flotation aids |
US4826866A (en) * | 1987-11-02 | 1989-05-02 | A. H. Robins Company, Incorporated | 3-amino-5-methyl-1H-pyrazole-4-carboxylic acids and esters thereof as anticonvulsants, muscle relaxants and anxiolytics |
RU2091366C1 (ru) * | 1992-06-16 | 1997-09-27 | Инесса Ивановна Крицкая | Натриевая соль бицикло(2.2.2.)октан -2-карбоновой кислоты, проявляющая противосудорожную активность |
Non-Patent Citations (1)
Title |
---|
MASHKOVSKY M.D., Lekarstvennye Sredstva, Chast II, Moscow, MEDITSINA, 1993, pages 111-112. * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010071872A2 (fr) | 2008-12-20 | 2010-06-24 | Ase Pharmaceuticals, Llc | Dérivés bicycliques (2.2.2) et leurs procédés d'utilisation |
WO2010071872A3 (fr) * | 2008-12-20 | 2010-11-25 | Ase Pharmaceuticals, Llc | Dérivés bicycliques (2.2.2) et leurs procédés d'utilisation |
CN102300573A (zh) * | 2008-12-20 | 2011-12-28 | 苏珊娜·A·萨基扬 | [2.2.2]双环衍生物及其使用方法 |
JP2012512913A (ja) * | 2008-12-20 | 2012-06-07 | サアキアン,スザンナ,エイ. | [2.2.2]二環式誘導体及び使用方法 |
AU2009327316B2 (en) * | 2008-12-20 | 2015-06-04 | Ase Pharmaceuticals, Llc | [2.2.2] bicyclic derivatives and methods of use |
US20170000750A1 (en) * | 2008-12-20 | 2017-01-05 | Ase Pharmaceuticals, Llc | [2.2.2] bicyclic derivatives and methods of use |
CN106309418A (zh) * | 2008-12-20 | 2017-01-11 | 艾思益制药有限责任公司 | [2.2.2]双环衍生物及其使用方法 |
KR101840178B1 (ko) * | 2008-12-20 | 2018-03-19 | 에이에스이 파마수티컬스, 엘엘씨. | 〔2.2.2〕비시클릭 유도체 및 사용방법 |
US9943493B2 (en) * | 2008-12-20 | 2018-04-17 | Ase Pharmaceuticals, Llc | [2.2.2] bicyclic derivatives and methods of use |
RU2691406C2 (ru) * | 2008-12-20 | 2019-06-13 | ЭйЭсИ Фармасьютикалз, ЭлЭлСи | [2.2.2]-бициклические производные и способы применения |
US10966944B2 (en) * | 2008-12-20 | 2021-04-06 | Ase Pharmaceuticals, Llc | [2.2.2] bicyclic derivatives and methods of use |
Also Published As
Publication number | Publication date |
---|---|
AU6425498A (en) | 1999-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Manno et al. | Toxicology of ipecac: a review | |
HUE033687T2 (en) | Ibuprofen positively charged water soluble prodrugs with very fast skin penetration rates | |
JPS58134031A (ja) | 多発性硬化症処置におけるジヒドロシクロスポリンd | |
EA030385B1 (ru) | Применение комбинации, содержащей баклофен и акампросат или торасемид, для улучшения памяти | |
US5643954A (en) | Method of preventing and alleviating stress in a healthy mammal in need thereof | |
JPH0193517A (ja) | 医薬組成物 | |
US4096278A (en) | Organic derivatives of montmorillonite for treating lipid disturbances | |
WO1999023056A1 (fr) | Nouveaux medicaments anti-convulsions | |
WO1995034304A1 (fr) | Derives de 2-mercaptobenzimidazole pharmacologiquement actifs | |
US4608258A (en) | Medicament for treatment of diarrhea | |
JPS5829708A (ja) | 痙「れん」 | |
US3056726A (en) | alpha-ethyl-beta-methylvaleramide for mental hyperirritability | |
WO1991016046A1 (fr) | Emploi de derives d'acide carboxylique d'acetoacetyle dans l'immunosuppression | |
DE3111770C2 (fr) | ||
JPS58502000A (ja) | 置換ピロ−ル | |
US3065136A (en) | Treatment of vascular diseases with 2-aminoethanol-1-nitrate salt of p-toluene sulfonic acid | |
EP1124555A1 (fr) | Procede de traitement des maladies neurodegeneratives | |
US4446132A (en) | Nontoxic aspirin composition | |
DE2441206A1 (de) | 1- oder 2-mono- und -dialkylsubstituierte thienobenzopyrane | |
RU2723165C9 (ru) | Способ снижения тяжести отдаленных последствий отравлений оксидом углерода | |
RU2363463C1 (ru) | Лекарственное средство | |
DE2038836B2 (de) | Arzneimittel | |
RU2116792C1 (ru) | Композиция с противоязвенным эффектом | |
US2085794A (en) | Urinary antiseptic | |
SU1512056A1 (ru) | @ -Антранилоилгидразид нтарной кислоты гидрохлорид, про вл ющий антиагрегантную активность по отношению к тромбоцитам плазмы крови |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |